The only thing I didn't like was that Dacogen sales this quarter included a 1.9M defered revenues. They took a page out of SUPG playbook. I'm beginning to hate deferred revenues. We have to wait to hear what PHRM states about growth. The run up in their stock price is going to want to hear about growth. I see sales flat on Vidaza and they also have to contend with Thanksgiving and Christmas. The analyst are going to be asking some hard questions over there. They will want to cut in run if they do not hear something positive. The previous quidance was 105-115M, so we did get a rise in guidance. IMHO MGI is now in a position with two strong growth drugs to understate and over delivery.
They announced last quarter on the 25th. Any delay may signal some uncertainities in how to explain flat sales for the 3 quarters. If Md's are not signally them that they're on board, it could get hairy. I believe they will point towards the 55% of MD's that are only using standard care and say that they expect growth. But they will not give any figures, remember most of the insiders sold into this news. They will not want to open any lawsuits up by over expressing growth. I expect a very somber presentation by PHRM. The IMS figures do not support growth and how do they answer the question?????